Feraheme has been approved to treat iron deficiency in adult chronic kidney disease patients, but the U.S. Food and Drug Administration has refused to clear the drug for use among patients suffering from adult iron …
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG)‘s stock had its “hold” rating reaffirmed by research analysts at JPMorgan Chase & Co. in a research report issued on Friday. They presently have a $33.00 price target on …
Investors have taken a wild ride with AMAG Pharmaceuticals (NASDAQ: AMAG) in the last two years. A series of acquisitions that began in 2014 propelled the stock to all-time highs two summers ago, reaching levels over …
AMAG Pharmaceuticals
Even though AMAG Pharmaceuticals Inc generates substantial revenue, its market cap is small enough that just the fact that it's a biotechnology pharmaceutical company, in and of itself, makes AMAG susceptible to …
AMAG) during the third quarter, Holdings Channel reports. The fund owned 182,301 shares of the specialty pharmaceutical company’s stock at the end of the third quarter. Boston Partners’ holdings in AMAG
Boston
Collecting that bid as the premium represents a 7.7% return against the $26 commitment, or a 12.1% annualized rate of return (at Stock Options Channel we call this the YieldBoost). Selling a put does not give an investor …
NASDAQ
aMaG Pharmaceuticals, Inc. (NaSDaQ:aMaG) stock has moved in a downward direction over the past week, …
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) stock is down over 12% today, after the company disclosed financial results for first quarter of fiscal 2016 (1QFY16). The company missed the Street’s expectations for …
Below is a chart showing the trailing twelve month trading history for AMAG Pharmaceuticals, Inc., and highlighting in green where the $19 strike is located relative to that history: The chart above, and the stock’s …